Recent progress in the application of analytical techniques to anticancer metallodrug proteomics (Q58856071)

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

The use of inductively coupled plasma mass spectrometry as a detector in drug metabolism studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

The emerging role of ICP-MS in proteomic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Capillary electrophoresis of metal-based drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

CE in anticancer metallodrug research--an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Metallodrug research and analysis using capillary electrophoresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Analytical methodologies for metallomics studies of antitumor Pt-containing drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Recent developments in ruthenium anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Advances in developing tris(8-quinolinolato)gallium(iii) as an anticancer drug: critical appraisal and prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

A review of recent trends in electrospray ionisation-mass spectrometry for the analysis of metal-organic ligand complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Determination of binding sites in carboplatin-bound cytochrome c using electrospray ionization mass spectrometry and tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Direct determination of the primary binding site of cisplatin on cytochrome C by mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Reaction of Zn7Metallothionein withcis- andtrans-[Pt(N-donor)2Cl2] Anticancer Complexes: trans-PtIIComplexes Retain Their N-Donor Ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Thiolate bridging and metal exchange in adducts of a zinc finger model and Pt(II) complexes: biomimetic studies of protein/Pt/DNA interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Peculiar mechanistic and structural features of the carboplatin-cytochrome c system revealed by ESI-MS analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Reaction of human metallothionein-3 with cisplatin and transplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

New platinum-oxicam complexes as anti-cancer drugs. Synthesis, characterization, release studies from smart hydrogels, evaluation of reactivity with selected proteins and cytotoxic activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

A mass spectrometric comparison of the interactions of cisplatin and transplatin with myoglobin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Platination of superoxide dismutase with cisplatin: tracking the ammonia ligands using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Top-down characterization of proteins and drug-protein complexes using nanoelectrospray tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Characterization of intact hemoglobin and oxaliplatin interaction by nanoelectrospray ionization tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Shape changes induced by N-terminal platination of ubiquitin by cisplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

ESI–MS Characterisation of Protein Adducts of Anticancer Ruthenium(II)-Arene PTA (RAPTA) Complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Ruthenium anticancer drugs and proteins: a study of the interactions of the ruthenium(III) complex imidazolium trans-[tetrachloro(dimethyl sulfoxide)(imidazole)ruthenate(III)] with hen egg white lysozyme and horse heart cytochrome c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Trans-cis-cis-[RuCl2(DMSO)2(2-amino-5-methyl-thiazole)2], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Rhenium inhibitors of cathepsin B (ReO(SYS)X (where Y = S, py; X = Cl, Br, SPhOMe-p)): Synthesis and mechanism of inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

[Au2(phen(2Me))2(μ-O)2](PF6)2, a Novel Dinuclear Gold(III) Complex Showing Excellent Antiproliferative Properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]− to human serum albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Strategy To Tether Organometallic Ruthenium−Arene Anticancer Compounds to Recombinant Human Serum Albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Mass spectrometric analysis of ubiquitin–platinum interactions of leading anticancer drugs: MALDI versus ESI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Proteomic analysis of cisplatin-induced cochlear damage: methods and early changes in protein expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Rational design of an organometallic glutathione transferase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Top-down mass spectrometric approach for the full characterization of insulin-cisplatin adducts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Targeting retroviral Zn finger-DNA interactions: a small-molecule approach using the electrophilic nature of trans-platinum-nucleobase compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Platinum(II) compounds with chelating ligands based on pyridine and pyrimidine: DNA and protein binding studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Activity of Rat Cytosolic Thioredoxin Reductase Is Strongly Decreased bytrans-[Bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: First Report of Relevant Thioredoxin Reductase Inhibition for a Ruthenium Compound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

fac-{Ru(CO)3}2+-core complexes and design of metal-based drugs. synthesis, structure, and reactivity of Ru-thiazole derivative with serum proteins and absorption-release studies with acryloyl and silica hydrogels as carriers in physiological media.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Structural investigation of cisplatin-protein interactions: selective platination of His19 in a cuprozinc superoxide dismutase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Platinum complex as a nanomolar protein kinase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Extremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Long-term platinum retention after treatment with cisplatin and oxaliplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Mono- and polynuclear [alkylamine]platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

The serum protein binding of pharmacologically active gallium(III) compounds assessed by hyphenated CE-MS techniques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

A versatile approach for assaying in vitro metallodrug metabolism using CE hyphenated with ICP-MS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Probing the stability of serum protein–ruthenium(III) drug adducts in the presence of extracellular reductants using CE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Toward high-throughput monitoring of metallodrug-protein interaction using capillary electrophoresis in chemically modified capillaries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(iii) compound with plasma proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Interactions of a novel ruthenium-based anticancer drug (KP1019 or FFC14a) with serum proteins--significance for the patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Preclinical characterization of anticancer gallium(III) complexes: solubility, stability, lipophilicity and binding to serum proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and anti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

The effects of drug complexation on the stability and conformation of human serum albumin: protein unfolding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Characterization of interactions between human serum albumin and tumor-inhibiting amino alcohol platinum(II) complexes using capillary electrophoresis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Investigation of interaction between human hemoglobin A0 and platinum anticancer drugs by capillary isoelectric focusing with whole column imaging detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Human serum albumin interaction with oxaliplatin studied by capillary isoelectric focusing with the whole column imaging detection and spectroscopic method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Mass spectrometry study of hemoglobin-oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Intact human holo-transferrin interaction with oxaliplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Speciation analysis of platinum antitumoral drugs in impacted tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

On-line fast column switching SEC × IC separation combined with ICP-MS detection for mapping metallodrug–biomolecule interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Novel insights into the bottom-up mass spectrometry proteomics approach for the characterization of Pt-binding proteins: The insulin-cisplatin case study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Stability, accumulation and cytotoxicity of an albumin-cisplatin adduct.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Specific determination of intact cisplatin and monohydrated cisplatin in human plasma and culture medium ultrafiltrates using HPLC on-line with inductively coupled plasma mass spectrometry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Alternative organic solvents for HILIC separation of cisplatin species with on-line ICP-MS detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007

Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRAC.2011.03.007